AcelRx pain treatment as effective as standard care in trial

(Reuters) – AcelRx Pharmaceuticals Inc said its drug-device combination for post-operative pain was at least as effective as the standard of care, suggesting it has the potential to replace the current treatment. AcelRx plans to file for marketing approval for the device in the third quarter of 2013, Pamela Palmer, co-founder and chief medical officer of AcelRx said on a conference call with analysts. The company’s stock jumped 42 percent to a year high of $4.55 in heavy volume trade on Thursday, making it the third biggest percentage gainer on the Nasdaq. …